EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Unplanned hospitalization among advanced prostate cancer patients by diabetes status: a population-based study

Amy L Shaver iD, Krupa Gandhi iD, Scott W Keith iD, Nikita Nikita iD, Christopher C Yang iD, Felix J Kim iD, Hushan Yang, William Kevin Kelly, Stephen J Freedland iD, Grace Lu-Yao iD

JNCI Cancer Spectrum · 2025

DOI: 10.1093/jncics/pkaf070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2025. Verfasst von Amy L Shaver und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Population Science, Department of Medical Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, Unite…. Hauptthemen laut MEDLINE: Hospitalization, Prostatic Neoplasms, Diabetes Mellitus, Type 2, Androgen Receptor Antagonists. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Older adults with advanced prostate cancer and type 2 diabetes mellitus are underrepresented in trials of androgen receptor pathway inhibitors. This study examined changes in unplanned hospitalization rates in patients receiving androgen receptor pathway inhibitors by type 2 diabetes mellitus status and assessed if unplanned hospitalization varies according to androgen receptor pathway inhibitors.

Methods

This population-based study of advanced prostate cancer patients aged older than 66 years used Surveillance, Epidemiology, and End Results–Medicare data. Prepost androgen receptor pathway inhibitor initiation changes and androgen receptor pathway inhibitor differences in unplanned hospitalization rates were estimated by adjusted incidence rate ratio with considerations for interactions between period, androgen receptor pathway inhibitor, and type 2 diabetes mellitus status. Linear contrasts were used to estimate and test conditional incidence rate ratios. Tests were 2-sided, and a P value less than .05 was considered statistically significant.

Results

The study included 12 240 patients: 3160 (25.8%) with type 2 diabetes mellitus, 7191 (58.8%) received abiraterone acetate with prednisone, and 5049 (41.2%) received enzalutamide. Unplanned hospitalization rates increased after androgen receptor pathway inhibitor initiation by 65% among patients with type 2 diabetes mellitus complications (adjusted incidence rate ratio = 1.65, 95% confidence interval [CI] = 1.37 to 1.98) and 109% in nondiabetics (adjusted incidence rate ratio = 2.09, 95% CI = 1.94 to 2.26). Among patients with type 2 diabetes mellitus without complications, the increase in unplanned hospitalization rates depended on the androgen receptor pathway inhibitor initiated: 103% after abiraterone acetate with prednisone (adjusted incidence rate ratio = 2.03, 95% CI = 1.70 to 2.43) and 47% after enzalutamide (adjusted incidence rate ratio = 1.47, 95% CI = 1.21 to 1.80) and a 38% greater increase in unplanned hospitalization rates after abiraterone acetate with prednisone than enzalutamide (ratio of abiraterone acetate with prednisone adjusted incidence rate ratio divided by enzalutamide adjusted incidence rate ratio = 1.38, 95% CI = 1.06 to 1.80).

Conclusions

All patients had higher unplanned hospitalization rates after androgen receptor pathway inhibitor. Our findings highlight the importance of using real-world data to better understand the interplay between preexisting health conditions and treatment outcomes, a critical step toward precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HospitalizationProstatic NeoplasmsDiabetes Mellitus, Type 2Androgen Receptor AntagonistsHumansMaleAgedPhenylthiohydantoinSEER ProgramNitrilesAged, 80 and overBenzamidesPrednisoneAbiraterone AcetateUnited StatesAndrogen AntagonistsMedicare

Substanzen

enzalutamidePhenylthiohydantoinNitrilesBenzamidesPrednisoneAbiraterone AcetateAndrogen Receptor AntagonistsAndrogen Antagonists

Autor:innen und Institutionen

  • Division of Population Science, Department of Medical Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, United States.
  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia, PA, United States.
  • Division of Biostatistics and Bioinformatics, Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, United States.
  • College of Computing and Informatics, Drexel University, Philadelphia, PA, United States.
  • Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, United States.
  • Division of Solid Tumor, Department of Medical Oncology, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, United States.

ORCID-Profile: Amy L Shaver, Krupa Gandhi, Scott W Keith, Nikita Nikita, Christopher C Yang, Felix J Kim, Stephen J Freedland, Grace Lu-Yao

Förderung

  • NCI NIH HHS

Zitieren

APA

Shaver, A. L., Gandhi, K., Keith, S. W., Nikita, N., Yang, C. C., Kim, F. J., Yang, H., Kelly, W. K., Freedland, S. J., & Lu-Yao, G. (2025). Unplanned hospitalization among advanced prostate cancer patients by diabetes status: a population-based study. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkaf070

Vancouver

Shaver AL, Gandhi K, Keith SW, Nikita N, Yang CC, Kim FJ, et al. Unplanned hospitalization among advanced prostate cancer patients by diabetes status: a population-based study. JNCI Cancer Spectrum. 2025. doi:10.1093/jncics/pkaf070

BibTeX
@article{Shaver2025,
  author = {Shaver, Amy L and Gandhi, Krupa and Keith, Scott W and Nikita, Nikita and Yang, Christopher C and Kim, Felix J and Yang, Hushan and Kelly, William Kevin and Freedland, Stephen J and Lu-Yao, Grace},
  title = {Unplanned hospitalization among advanced prostate cancer patients by diabetes status: a population-based study},
  journal = {JNCI Cancer Spectrum},
  year = {2025},
  doi = {10.1093/jncics/pkaf070}
}
Kostenlos starten →